We use cookies on this website. By using the website you accept our use of cookies. Accept

News Archive

 

ACACIA PHARMA ANNOUNCES POSITIVE RESULTS FROM...

ACACIA PHARMA ANNOUNCES POSITIVE RESULTS FROM ITS FOURTH AND FINAL PIVOTAL TRIAL OF BAREMSIS™ FOR THE RESCUE TREATMENT OF PONV

Extensive Phase 3 programme demonstrates clinical potential of BAREMSIS in rescue treatment and prophylaxis of PONV – NDA to be submitted to the US FDA 1H 2017

Cambridge, UK – 13th February 2017

Acacia Pharma Group Ltd (“Acacia Pharma”), the supportive care company developing products for US and international markets, announces positive results from its fourth and final pivotal Phase 3 study investigating BAREMSIS™ (amisulpride injection, formerly APD421) for the rescue treatment of patients who develop post-operative nausea & vomiting (PONV), despite having received prior antiemetic prophylaxis. 

Please click here to read the full press release from Acacia.
 

Luk

ERT Recognized for Improving and Accelerating...

ERT Recognized for Improving and Accelerating Clinical Research

February 16, 2017

Company Named Finalist for PACT Technology Company of the Year Award

ERT, a global data and technology company that minimizes risk and uncertainty in clinical trials, today announced it has been named a finalist for the Philadelphia Alliance for Capital and Technologies (PACT) Technology Company of the Year Award. ERT is one of only three companies nominated to receive this recognition.

Click here to read ERT's news release.
 

Luk

BTG and Society of Interventional Oncology to...

BTG and Society of Interventional Oncology to explore role of minimally invasive therapies in immuno-oncology

15 February 2017

London, UK: BTG plc (LSE: BTG), the global specialist healthcare company, today announced a collaboration with the Society of Interventional Oncology (SIO), a global organization working to nurture and support interventional oncology worldwide, to explore the role of interventional oncology alongside immuno-oncology.

Click here to read BTG's press release.

Luk

Novo A/S becomes new long-term strategic...

Novo A/S becomes new long-term strategic shareholder in Evotec

Please see here for more information.

Luk

Lysogene receives Orphan Drug Designation from...

Lysogene receives Orphan Drug Designation from FDA for LYS-GM101 for treatment of GM1 Gangliosidosis

Click here to read Lysogene's press release.

Luk

Chr. Hansen Holding A/S - Major shareholder...

Chr. Hansen Holding A/S - Major shareholder announcement from BlackRock, Inc.

Hoersholm, 2017-02-01 15:43 CET (GLOBE NEWSWIRE) -- 

Click here to read Chr. Hansen's company announcement no. 4/2017.

Luk

Lilly and CoLucid Pharmaceuticals Announce...

Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid

$960 million deal will enhance Lilly’s existing pain management portfolio for migraine; adds potential near-term launch to its late-stage pipeline

INDIANAPOLIS, IN and CAMBRIDGE, MA, January 18, 2017–

Eli Lilly and Company (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) today announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approximately $960 million. This all-cash transaction will enhance Lilly’s existing portfolio in pain management for migraine, while adding a potential near-term launch to its late-stage pipeline.

Click here to read CoLucid's news release.

Luk

Chr. Hansen - Q1 Results: A good start to the...

Chr. Hansen - Q1 Results: A good start to the year

Chr. Hansen has had a good start to the year with strong organic revenue growth of 11% in Q1 2016/17, which is better than initially expected for the quarter. Revenue reached EUR 242 million – 13% above last year.

Click here to read the full press release.
 

Luk

First Pulmonary Embolism Patients in Hong Kong...

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® system

10 January 2017

BTG plc (LSE: BTG), the global specialist healthcare company, today announced the first patients diagnosed with Pulmonary Embolism (PE) to be treated in Hong Kong using the newly available EKOS® system. The EKOS® system includes an ultrasonic device that uses acoustic pulses to quickly and safely dissolve blood clots and restore blood flow in patients with PE, deep vein thrombosis (DVT), and peripheral arterial occlusions (PAO).

Click here to read the full news release from BTG.
 

Luk

Anokion Announces Exclusive Strategic...

Anokion Announces Exclusive Strategic Collaboration with Celgene to Develop Novel Tolerance-Inducing Therapeutics for Autoimmune Diseases

 

LAUSANNE, Switzerland, and CAMBRIDGE, MA January 9, 2017

Anokion, a privately held biopharmaceutical company developing novel tolerance-inducing therapeutics for autoimmune diseases, today announced the formation of an exclusive global research collaboration with Celgene Switzerland LLC, an affiliate of Celgene Corp.

Click here to read the full news release from Anokion.

Luk

HepaRegeniX GmbH Raises €9 million in a Series...

HepaRegeniX GmbH Raises €9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of

Tubingen (Germany), January 05, 2017

HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today the completion of a €9 million Series A financing. The round was led by Boehringer Ingelheim Venture Fund GmbH (BIVF) and Novo Seeds, and complemented by the High-Tech Gruenderfonds and coparion.

HepaRegeniX develops a new and unique therapeutic concept for the treatment of liver diseases, discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany. In the healthy liver, hepatocytes have a near endless capacity to regenerate. However, in liver diseases, this regenerative capacity is locked and excessive hepatocyte death cannot be compensated, ultimately leading to loss of liver function and often death. 

Click here to read the full press release.

Luk

IO Biotech closes Series A Round including new...

IO Biotech closes Series A Round including new investor Sunstone Capital to the investor syndicate

Copenhagen, Denmark – December 28, 2016

IO Biotech today announced successful closure of the €8.5 million second tranche series A investment round. Participants were existing investors Lundbeckfonden and Novo Seeds plus new investor Sunstone Capital.

Click here to read IO Biotech's news release.
 

Luk

Incyte and Merus Announce Global Strategic...

Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies

UTRECHT, The Netherlands, Dec. 21, 2016 (GLOBE NEWSWIRE)

Today, Merus N.V. (NASDAQ:MRUS) and Incyte Corporation (NASDAQ:INCY) announced that they have entered a global strategic research collaboration focused on the research, discovery and development of bispecific antibodies utilizing Merus’ proprietary Biclonics® technology platform. The Collaboration and License Agreement grants Incyte the exclusive rights for up to eleven bispecific antibody research programs, including two of Merus’ current preclinical immuno-oncology discovery programs. To view the press release, please click here.

Merus will host a conference call today to discuss this strategic research collaboration at 8:30 a.m. ET, 2:30 p.m. CET. Participants may access the call by dialing 866-978-9968 in the U.S. or 646-722-4972 outside the U.S. and referencing conference ID number 72944512#. The conference call will also be available by webcast on the Investor Relations page of Merus’ website, www.merus.nl. An audio replay of the call will be available from 11:30 a.m. ET on December 21, 2016 until 11:30 a.m. ET on January 4, 2017. To access the replay from both within and outside the U.S., dial 866-535-8030. The participant passcode is 680343#.

Contacts:

Eliza Schleifstein, Media
+1 973 361 1546 
eliza@argotpartners.com 

Kimberly Minarovich, Investors
+1 646 368 8014
kimberly@argotpartners.com 

Luk

Novo A/S becomes a strategic investor in SYNLAB

Novo A/S becomes a strategic investor in SYNLAB

Novo A/S exercises its option for an equity stake in SYNLAB of more than 10%

Munich / Hellerup, 15 December 2016 – SYNLAB Limited ("SYNLAB" or "the Group") and Novo A/S ("Novo"), the holding company for the Novo Group, today jointly announce that Novo has exercised its option to acquire a stake in the Group for more than 10% of the equity. Cinven remains the majority holder.

The closing of the transaction is scheduled to take place on 15 December 2016.

By exercising its option, Novo emphasizes its ongoing commitment as a strategic investor to facilitate SYNLAB’s expansion and development through significant financial backing for the Group. SYNLAB, established in 1998, is the European market leader for laboratory diagnostics. SYNLAB is growing organically by providing the highest-quality services in the industry. At the same time, the Group is pursuing a strategy of consolidating the laboratory diagnostics market and today is operating in more than 30 countries with total revenue of circa €1.6 billion.

Commenting on the decision of Novo, Bartl Wimmer, CEO of SYNLAB, said:

"Novo’s investment reflects its high level of confidence in SYNLAB’s robust performance, which we have demonstrated both since it acquired its share option in February this year and before that. The investment can also be regarded as a thorough evaluation of our strong growth story. I am looking forward to a fruitful relationship and mutual benefit for both companies."

Commenting on the investment in SYNLAB, Novo’s Large Investment responsible Michael Shalmi, said:

"We have closely followed the impressive development of SYNLAB throughout 2016, and we are very optimistic that SYNLAB will continue its positive trend in the future. With the exercise of the share option, we extend our commitment to SYNLAB as an important company in our portfolio, which is being built through investing in market leading, profitable life-science companies with favourable growth potential."

Forward-looking information is subject to risk and uncertainty

This press release may include certain "forward-looking" statements. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terms such as the words "believes", "expects", "may", "will", "would", "should", "seeks", "pro forma", "anticipates", "intends", "plans" and "estimates" or the negative of any thereof or other variations thereof or comparable terms or by discussions of strategy or intentions. These statements are not guarantees of future actions or performance and involve risks, uncertainties and assumptions as to future events that may not prove to be accurate. Actual actions or results may differ materially from what is expressed or forecasted in these forward-looking statements. As a result, these statements speak only as of the date they were made, and SYNLAB undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

About the SYNLAB Group

  • The SYNLAB Group is the leading laboratory services provider in Europe. SYNLAB offers a full range of innovative and reliable medical diagnostics for patients, practising doctors, clinics and the pharmaceutical industry.
  • Providing the leading level of service within the industry, SYNLAB is the partner of choice for healthcare professionals. SYNLAB’s services also encompass veterinary and environmental laboratory analysis. 
  •  SYNLAB operates in more than 30 countries across four continents and holds leading positions in most markets. Over 13,000 employees contribute every day to the Group’s success across different geographies. SYNLAB carries out 450 million laboratory tests per year, achieving sales revenue of circa €1.6 billion.
    Read more at www.synlab.com

 

About Novo A/S

  • Novo A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.
  • Novo A/S is the holding company in the Novo Group and responsible for managing the Foundation’s assets.
  • Besides being the major shareholder in the Novo Group companies, Novo A/S provides seed and venture capital to development-stage companies, takes significant ownership positions in well-established companies within the life sciences and manages a broad portfolio of financial assets. 
    Read more at www.novo.dk
     

For more information: SYNLAB

Daniel Herbert, FTI Consulting

+49 69 9203 7183

Daniel.Herbert@fticonsulting.com

Novo A/S

Michael Shalmi

+45 3067 4785

mish@novo.dk

Luk

Hoba Therapeutics launches with DKK 14 million...

Hoba Therapeutics launches with DKK 14 million in seed financing

New company focuses on developing a disease-modifying treatment for neuropathic pain.

Press release, Friday, 2 December 2016

Hoba Therapeutics, a biotechnology company focusing on developing disease-modifying treatments for neuropathic pain, has been formed based on a DKK 14 million (US$ 2 million) seed investment. Novo Seeds, part of Novo A/S, led the financing together with Danish investor BOREAN Innovation.

Click here to read the full press release.

Luk

Merus Announces Favorable Decisions in Europe...

Merus Announces Favorable Decisions in Europe and Japan for Patents Covering Genetically-Modified Mice for Common Light Chain Human Monoclonal Antibodies

European Patent Office Dismisses Arguments by Regeneron
Favorable Rulings Further Strengthen IP Estate in Europe and Japan through 2029

UTRECHT, The Netherlands, Nov. 15, 2016 (GLOBE NEWSWIRE) –

Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that it received two favorable rulings for its European patent EP 2147594 B1 (the “‘594 patent”) by the Opposition Division of the European Patent Office (the “EPO”) as well by the Trial Board of the Japanese Patent Office for its Japanese counterpart JP 5749161 (the “‘161 patent”). Both patents cover Merus’ genetically-modified mice and their use to produce common light chain human monoclonal antibodies.

Click here to read Merus’ full news release.

Luk

Acesion Pharma raises 9.1 million EUR in first...

Acesion Pharma raises 9.1 million EUR in first closing of new funding from Novo Seeds and Wellcome Trust

Acesion Pharma, a Danish biotech company developing novel treatments for atrial fibrillation (AF), today announced that it has raised 9.1 million EUR (10 million USD)in a first closing of a new investment round. The round includes current investors Wellcome Trust Ltd. and Novo Seeds, the early stage investment arm of Novo A/S. Wellcome Trust grants its funding in the form of a Translational Award and thereby continues on the Seeding Drug Discovery Initiative Award that it granted to Acesion in 2013.

Click here to read the full press release from Acesion Pharma.

Luk

ObsEva Randomizes First Patient in Phase 2b...

ObsEva Randomizes First Patient in Phase 2b EDELWEISS Study of OBE2109 for the Treatment of Endometriosis

  • Clinical trial to assess safety and efficacy of novel GnRH antagonist in patients with pelvic pain associated with endometriosis

 

GENEVA, SWITZERLAND, 12 October, 2016

ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced randomization of the first patient in its Phase 2b clinical study (EDELWEISS) of OBE2109 for the treatment of endometriosis. OBE2109 is a novel, orally administered, gonadotropin-releasing hormone (GnRH) antagonist that has been tested in more than 150 Japanese patients with endometriosis. In those Phase 2a studies, conducted by Kissei Pharmaceutical Co., Ltd. (Kissei), a dose-dependent suppression of estradiol was observed with treatment with OBE2109. In addition, patients reported significant reductions of endometriosis-associated pelvic pain, analgesic use and bleeding days.

Click here to read the full news release.

Luk

Reata Enrolls First Patient in Phase 3 CATALYST...

Reata Enrolls First Patient in Phase 3 CATALYST Trial of Bardoxolone Methyl in CTD-PAH Patients and Reports Positive Interim Data From CTD-PAH Patients in Phase 2 LARIAT Trial

• First Patient Has Been Enrolled In Phase 3 CATALYST Trial In CTD-PAH
• Updated Data from CTD-PAH Patients in Phase 2 LARIAT Trial Demonstrate Improvements Consistent with the Previously Reported Cohort 1 Data
• Design, Size, and Statistical Power of CATALYST are Adequate to Detect the Treatment Effect Observed in the Phase 2 LARIAT Trial
• Data from CATALYST are expected to be available in H1 2018

IRVING, Texas, Oct. 06, 2016

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) (“Reata” or “the Company”) today announced that it has enrolled the first patient into its Phase 3 trial (CATALYST) to evaluate the efficacy and safety of bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH).

Click here to read the full news release from Reata Pharmaceuticals.
 

Luk

Orexo - FDA Approves Unique Low Dosage of Zubsolv®

Orexo - FDA Approves Unique Low Dosage of Zubsolv®

Uppsala, Sweden – October 6, 2016

Orexo AB (publ.) announced today that it has received approval from the US Food and Drug Administration (FDA) of a new unique low dose, 0.7mg/0.18 mg, tablet of Zubsolv (buprenorphine/naloxone) sublingual tablet (CIII) for the treatment of opioid dependence. The new dosage is expected to be available in US pharmacies in early 2017.

Click here to read the full news release from Orexo.

Luk

Pages